THOUSAND OAKS, Calif., Aug. 29, 2022 /PRNewswire/ -- Amgen (AMGN) today presented new compelling data from the Phase 3 FOURIER open label extension (OLE) studies of Repatha ® (evolocumab) in adults ...
Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Philips NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results